rethinkPeptides Search
Menu
Study breakdown

How Repeated Hexarelin Dosing Affects Growth Hormone Release Over Time

Animal StudyModerate evidence
The takeaway

Repeated hexarelin doses maintain GH-releasing ability but show some desensitization, while continuous infusion leads to marked attenuation of GH response.

Pulsatile > continuous

Repeated discrete hexarelin doses maintained GH release, while continuous infusion led to marked desensitization

What the researchers found

Pulsatile hexarelin dosing maintained GH-releasing efficacy with modest desensitization, while continuous infusion caused marked attenuation of GH response, supporting intermittent dosing strategies.

Why it matters

This study provides direct evidence for why GHRP dosing protocols emphasize pulsatile rather than continuous administration. The body's GH secretagogue receptors desensitize with continuous stimulation, meaning timing and dosing frequency are critical for maintaining therapeutic benefit.

How the study worked

In vivo rat study comparing IV, subcutaneous, and oral repeated dosing versus continuous IV infusion of hexarelin, with serial GH measurements to quantify response patterns.

What this study cannot tell us

Rat study — desensitization kinetics may differ in humans. Short-term study — long-term desensitization patterns not characterized. Only hexarelin tested — other GHRPs may show different desensitization profiles.

How to read the evidence

Well-designed comparative animal study published in a respected endocrinology journal. Directly addresses clinically relevant dosing questions.

When this study was published

Published in 1998, this study established key principles about GHRP desensitization that continue to inform clinical dosing recommendations.

The bigger picture

The desensitization pattern observed here mirrors what's seen clinically with many peptide hormones and helps explain GHRP dosing recommendations. The principle that pulsatile stimulation is superior to continuous exposure is fundamental to GH secretagogue therapy and echoes the body's own pulsatile GH release pattern.

Questions still open

  • What is the optimal dosing interval to minimize hexarelin desensitization?
  • Does desensitization fully reverse after a washout period?
  • Do different GHRPs (ipamorelin, GHRP-2) show similar desensitization patterns?

Common questions

Why does continuous GHRP use stop working as well?
The GH secretagogue receptors in the brain and pituitary become desensitized with constant stimulation — they essentially turn down their sensitivity. Pulsatile dosing allows receptors to recover between doses, maintaining effectiveness.
What does this mean for people using GH-releasing peptides?
It supports the common practice of dosing GHRPs 2-3 times daily rather than continuously, and may also support cycling protocols with rest periods to prevent desensitization.

Read the original research

Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.

The Journal of endocrinology, 158(3), 367-75

Citation

Conley, L K; Gaillard, R C; Giustina, A; Brogan, R S; Wehrenberg, W B. (1998). Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats.. The Journal of endocrinology, 158(3), 367-75.